Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 11/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4648549 | 0.81 | CA2 (0.47) | LOXL3MBTL1LOXL2KMT2AMAOA | |
| SCHEMBL18643569 | 0.75 | LOX (0.59) | LOXL3MBTL1LOXL2KMT2AMAOA | |
| SCHEMBL3005886 | 0.73 | L3MBTL1 (0.43) | LOXL3MBTL1LOXL2KMT2AMEN1 | |
| SCHEMBL2117188 | 0.73 | L3MBTL1 (0.43) | LOXL3MBTL1LOXL2KMT2AMEN1 | |
| SCHEMBL16330265 | 0.70 | L3MBTL1 (0.44) | LOXL3MBTL1LOXL2KMT2AMEN1 | |
| SCHEMBL12619971 | 0.68 | LOX (0.70) | LOXLOXL2MAOA | |
| SCHEMBL4645445 | 0.67 | CA2 (0.44) | LOXLOXL2MAOA | |
| SCHEMBL11459274 | 0.67 | L3MBTL1 (0.51) | L3MBTL1KMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL45854 | 0.66 | — | — | |
| SCHEMBL17850539 | 0.66 | L3MBTL1 (0.37) | LOXL3MBTL1LOXL2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |